To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of TQ05105 in Participants With Mild Hepatic Impairment (Child-Pugh A), Moderate Hepatic Impairment (Child-Pugh B), and Healthy Subjects

This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.

Study Overview

• Status: Recruiting
• Conditions: Myelofibrosis
• Intervention / Treatment: Drug: TQ05105

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Wei Zhao, Doctor; Phone Number: 0531-85875449; Email: zhao4wei2@hotmail.com

Study Locations

• China
  • Henan
    • Luoyang, Henan, China, 471000
      • Recruiting
      • The First Affiliated Hospital of Henan University of Science & Technology
      • Contact: Caie Wang, Doctor; Phone Number: 13837915297; Email: 245454618@qq.com
  • Shandong
    • Jinan, Shandong, China, 250000
      • Not yet recruiting
      • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
      • Contact: Wei Zhao, Doctor; Phone Number: 0531-85875449; Email: zhao4wei2@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Voluntarily participate in the clinical trial and sign the informed consent form, with full understanding of the trial content, procedures, and potential adverse reactions.
• Patients (including partners) have no pregnancy plans or sperm/egg donation plans from screening until 6 months after the last dose of the investigational drug, and agree to use effective contraception.
• Aged 18-75 years (inclusive), regardless of gender.
• Male participants weigh ≥50.0 kg; female participants weigh ≥45.0 kg. Body mass index (BMI) = weight (kg)/height² (m²), with BMI ranging 18.0-32.0 kg/m² (inclusive).
• Patients can communicate effectively with investigators and comply with the trial protocol.

Additional Criteria for Participants with Normal Liver Function:

• Negative serum HBsAg and Hepatitis C Virus (HCV) antibody test results.
• Weight within ±10 kg of the average weight of groups A/B; age within ±10 years of the average age of groups A/B; gender distribution similar to groups A/B (±1 participant per gender).

Additional Criteria for Participants with Impaired Liver Function:

• Chronic liver injury caused by primary liver diseases (e.g., hepatitis B/C, non-alcoholic fatty liver disease, alcoholic liver disease) or clinically diagnosed cirrhosis, classified as Child-Pugh Grade A or B.
• Stable condition within 2 weeks prior to dosing as judged by the investigator.
• No medication within 4 weeks before screening, or stable treatment regimen for underlying diseases (including liver-protective therapy).

Exclusion Criteria:

• History or current diagnosis of severe/chronic diseases (e.g., digestive, respiratory, neurological, cardiovascular, hematological, endocrine, oncological, immunological, or psychiatric disorders) deemed unsuitable by the investigator (except primary liver diseases and complications in participants with impaired liver function).
• Conditions affecting drug absorption, distribution, metabolism, or excretion (e.g., dysphagia) or prior gastrointestinal resection impacting these processes.
• Use of strong/moderate CYP3A4, CYP2C9, or CYP2C19 inducers/inhibitors within 4 weeks before screening.
• Known hypersensitivity to TQ05105 tablet components or allergic constitution (e.g., allergy to ≥2 substances, drug allergy history, or prone to rash/eczema/asthma).
• Average daily smoking >5 cigarettes within 3 months before screening.
• Drug abuse history or positive urine drug screen within 3 months.
• For alcoholic liver disease participants: history of excessive drinking (>2 alcohol units/day) within 1 year; for others: such history within 3 months.
• Blood donation/loss ≥200 mL or plasmapheresis within 4 weeks before screening.
• Consumption of alcohol (or positive breath test), grapefruit juice, coffee, tea, cola, or chocolate within 48 hours before dosing.
• Creatinine clearance (CLcr) <60 mL/min.
• Pregnant/lactating women, positive pregnancy test, or unprotected sex within 2 weeks before screening.
• Positive HIV antibody or Treponema pallidum-specific antibody.
• Other factors deemed unsuitable by the investigator.

Additional Exclusions for Normal Liver Function Participants:

• Use of prescription/non-prescription drugs, herbal medicines, or supplements (e.g., vitamins) within 2 weeks before screening.
• The results of physical examination during the screening period, vital signs, clinical laboratory tests (blood cell analysis (five categories), blood biochemistry, coagulation function, urine routine examination with sediment), electrocardiogram, frontal and lateral chest X-rays, abdominal ultrasound (liver, gallbladder, pancreas, spleen), and urinary system ultrasound, etc., which showed abnormal results and were determined by the research doctor to have clinical significance.
• Patients in other drug trials within 3 months or 5 half-lives (whichever longer) before screening.

Additional Exclusions for Impaired Liver Function Participants:

• Had a history of liver transplantation;
• Patients with hepatic coma within 30 days before screening;
• Patients who had used drugs that might cause acute hepatotoxicity (such as halothane and methotrexate) within 3 months before screening;
• Patients with acute liver disease caused by drug or viral infection within 2 months before screening;
• With biliary cirrhosis, liver/bile duct obstruction, cholestatic liver disease and other diseases affecting biliary excretion;
• Patients with liver failure or liver cancer, or patients with a history of esophagogastric variceal bleeding, hepatic encephalopathy, severe portal hypertension, or a portasystemic shunt within 1 year before screening who were judged by the investigator to be ineligible for the trial;
• Patients with abnormal physical examination, vital signs, clinical laboratory tests (blood cell analysis (five classification), blood biochemistry, coagulation function, urine routine and sediment), AFP, electrocardiogram, chest X-ray, echocardiography, abdominal ultrasound (liver, gallbladder, pancreas and spleen), urinary ultrasound, and routine electroencephalogram (EEG) during the screening period and judged by the research doctors as not suitable for the study;
• Patients with massive ascites on ultrasound during the screening period who were assessed by the investigators as not suitable for the trial;
• Who participated in and used any investigational drug within 1 month before screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: A: Mild hepatic impairment (Child-Pugh A); A: 15 mg orally , single dose	Drug: TQ05105; Janus Kinase Inhibitors/Rho-associated Kinase (JAK/ROCK) inhibitors
Active Comparator: B: Moderate hepatic impairment (Child-Pugh B); B: 10 mg orally , single dose	Drug: TQ05105; Janus Kinase Inhibitors/Rho-associated Kinase (JAK/ROCK) inhibitors
Active Comparator: C: Normal; C: 15 mg orally , single dose	Drug: TQ05105; Janus Kinase Inhibitors/Rho-associated Kinase (JAK/ROCK) inhibitors

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak concentration (Cmax)	Maximum plasma drug concentration of TQ05105 and TQ12550	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Area under the concentration-time curve (AUC)	Area under the plasma concentration-time curve of TQ05105 and TQ12550	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Terminal elimination rate (λz)	First-order rate constant associated with the terminal (log-linear) elimination phase of TQ05105 and TQ12550	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24 hours after administration
Time-to-maximum concentration( Tmax) of TQ05105 and TQ12550	Time-to-maximum concentration	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration
Plasma half life (t1/2)	The time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half of TQ05105 and TQ12550	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24, 48hours after administration
Apparent volume of distribution (Vz/F)	Apparent Volume of Distribution at the Terminal Phase divided by Bioavailability	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24, 48hours after administration
Curve extrapolated to infinity (AUC_%Extrap)	Percentage of the Area Under the Curve extrapolated to infinity	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24 hours after administration
Apparent Clearance (CL/F)	The apparent volume of plasma from which the drug is completely removed per unit time, adjusted for bioavailability	Before administration, 10, 20, 30, 45 minuets，1, 2, 3, 4, 6, 8, 12, 24 hours after administration
Fraction unbound(fu%)	The proportion of a drug or substance in the bloodstream that is not bound to plasma proteins and is therefore free to exert pharmacological activity, be metabolized, or undergo elimination.	0.5, 2, 6 hours after administration
Adverse event rate	The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).	Baseline up to day7

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: March 14, 2026
• First Submitted That Met QC Criteria: March 14, 2026
• First Posted (Actual): March 18, 2026

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: April 3, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Bone Marrow Diseases; Myeloproliferative Disorders; Hemic and Lymphatic Diseases; Primary Myelofibrosis
• Other Study ID Numbers: TQ05105-I-08

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No